万泰生物重组三价轮状病毒亚单位疫苗临床试验申请获受理

Core Viewpoint - Wantai Biological Pharmacy's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received the acceptance notice from the National Medical Products Administration for its clinical trial application of the "Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)" [1] Group 1 - The vaccine is produced using genetic engineering recombinant technology with an Escherichia coli expression system [1] - The main active ingredient of the vaccine is a truncated rotavirus spike protein VP4 [1]